Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Introduction. The distal tibia and fibula are rare sites of involvement by primary and metastatic tumors. For a long time, amputation remained the standard surgical intervention for this location. Oncological ankle replacement is associated with a number of difficulties, including a lack of soft tissue necessary to cover the implant, close proximity of anatomical structures, a high probability of vascular and infectious complications, and difficulties in restoring the biomechanics of the lost joint. Currently, due to the small number of analyzed groups and short-term observations, there is no generalized data on primary and revision oncological ankle replacement, and there is no developed approach to treatment and prevention of complications.Aim. To generalize the analysis of long-term results, the structure of complications, and functional results in a group of patients after primary and revision oncological ankle replacement in a statistically significant group of patients.Materials and methods. The study included 40 patients with benign bone tumors, primary localized sarcomas of bone and soft tissue, and metastatic lesions, which, since 2008, until 2023 56 primary and revision endoprosthetics of postresection defect of the distal tibia were performed. Over a period of 15 years, the study group included 40 (71.4 %) surgeries in the scope of primary endoprosthetics and 16 (28.6 %) surgeries in the scope of revision oncological endoprosthetics of the ankle joint.Results. Over a 15-year follow-up period, the overall incidence of complications, structured according to the International Society of limb Salvage (ISOLS) 2013 classification, after primary and revision arthroplasty was 50 %. The average time until detection of oncological and non-oncological complications was 16.1 months. The leading complication after endoprosthetics was aseptic instability (Type II; 21.4 %) and tumor recurrence (Type V) – 20 %. The average functional outcome after primary and revision ankle replacement was assessed using the MSTS scale and was 72 % after 6 months and ranged from 43 to 97 %. After 12 months, this figure was 78 % and ranged from 49 to 97 %.Conclusion. An objective assessment and increase in the statistical reliability of the results of oncological ankle replacement requires a larger number of surgeries, a longer observation period and joint consolidation of data from various clinics. Development of indications for such reconstructive operations, careful selection of patients taking into account the effect of conservative treatment allows to reduce the total number of complications, the number of local relapses and achieve a good functional result.
Introduction. The distal tibia and fibula are rare sites of involvement by primary and metastatic tumors. For a long time, amputation remained the standard surgical intervention for this location. Oncological ankle replacement is associated with a number of difficulties, including a lack of soft tissue necessary to cover the implant, close proximity of anatomical structures, a high probability of vascular and infectious complications, and difficulties in restoring the biomechanics of the lost joint. Currently, due to the small number of analyzed groups and short-term observations, there is no generalized data on primary and revision oncological ankle replacement, and there is no developed approach to treatment and prevention of complications.Aim. To generalize the analysis of long-term results, the structure of complications, and functional results in a group of patients after primary and revision oncological ankle replacement in a statistically significant group of patients.Materials and methods. The study included 40 patients with benign bone tumors, primary localized sarcomas of bone and soft tissue, and metastatic lesions, which, since 2008, until 2023 56 primary and revision endoprosthetics of postresection defect of the distal tibia were performed. Over a period of 15 years, the study group included 40 (71.4 %) surgeries in the scope of primary endoprosthetics and 16 (28.6 %) surgeries in the scope of revision oncological endoprosthetics of the ankle joint.Results. Over a 15-year follow-up period, the overall incidence of complications, structured according to the International Society of limb Salvage (ISOLS) 2013 classification, after primary and revision arthroplasty was 50 %. The average time until detection of oncological and non-oncological complications was 16.1 months. The leading complication after endoprosthetics was aseptic instability (Type II; 21.4 %) and tumor recurrence (Type V) – 20 %. The average functional outcome after primary and revision ankle replacement was assessed using the MSTS scale and was 72 % after 6 months and ranged from 43 to 97 %. After 12 months, this figure was 78 % and ranged from 49 to 97 %.Conclusion. An objective assessment and increase in the statistical reliability of the results of oncological ankle replacement requires a larger number of surgeries, a longer observation period and joint consolidation of data from various clinics. Development of indications for such reconstructive operations, careful selection of patients taking into account the effect of conservative treatment allows to reduce the total number of complications, the number of local relapses and achieve a good functional result.
Introduction. Currently, the achievements of oncological hip replacement play an important role in the treatment and rehabilitation of patients with a tumor lesion of the proximal femur. The study objective – to evaluate the effectiveness of the use of the acetabulum component with double mobility in oncological hip replacement. Materials and methods. Our prospective study included 108 patients operated in the Department of Bone Oncology of the R.R. Vreden National Medical Research Center of Traumatology and Orthopedics, Ministry of Health of Russia for a tumor lesion of the proximal femur in the period from 2014 to 2019. There were 65 (60.2 %) women, 43 (39.8 %) men. The median age was 52.1 years. Primary malignant bone tumors were identified in 19 (17.6 %) cases; benign aggressive and tumor-like diseases in 18 (16.6 %) cases; metastatic lesion in 71 (65.8 %) cases. Patients operated with bipolar heads were included in Group 1B – 53 (49 %). The 2D Group included 55 (51 %) patients operated with the use of the acetabulum component with dual mobility. Classification and analysis of complications was carried out according to the international system International Society of Limb Salvage 2014 (ISOLS 2014). The functional result was evaluated using the international Musculoskeletal Tumor Society (MSTS) system and the Harris Orthopedic scale (Harris Hip Score) in terms of 3, 6 and 12 months. Results. The total number of complications detected during the follow-up period from 2014 to 2020 was 13 (12 %) cases. Type I complications (ISOLS 2014) were represented by dislocation of the endoprosthesis – subtype IA, which was detected in 7 (6.4 %) patients operated with bipolar heads. There were no cases of dislocation of the endoprosthesis in the group operated with the use of double mobility (p = 0.006). We were able to identify a statistically significantly better functional result in patients operated with using of double mobility at all follow-up periods, both on the MSTS scale and on the Harris scale (p = 0.004). The five-year survival rate for aggressive benign tumors and tumor-like diseases was 92 %; for malignant primary tumors – 82 %; in patients with secondary bone lesions – 60 %. Conclusion. Today, oncological hip replacement, is still lags behind in functional results from primary standard hip arthroplasty, and the number of complications is still several times higher. We consider that one of the solutions of this problem, is a wider use of acetabulum components with dual mobility in oncoortopedic practice.
Introduction Acute hematogenous osteomyelitis can persist as chronic infection in pediatric patients due to delayed diagnosis and treatment. An extended bone defect of the limb caused by osteomyelitic destruction is a rare clinical scenario in pediatric surgery. Metaepiphyseal and articular involvement suggests specific and long-term treatment with a high risk of disability.The objective was to report a clinical case of a teenager who suffered chronic hematogenous osteomyelitis of the tibial bones and raise awareness of primary diagnosis and treatment.Material and methods A clinical case of a teenager treated for extensive destruction of the tibial bones caused by chronic hematogenous osteomyelitis is reported. Clinical and functional evaluation of the effectiveness was produced at the stages of treatment.Results A positive functional result was achieved due to staged surgical treatment including radical debridement of the chronic infection nidus followed by total ankle arthroplasty.Discussion Acute hematogenous osteomyelitis persisting as chronic infection could be caused either by a wait-and-see strategy when the patient first sought medical help or a long-term follow-up. There is no consensus on the use of reconstruction or replacement of large long bone defects extended to the joints caused by chronic infection. Staged treatment including total joint replacement with custom-made endoprosthesis can be one of the options.Conclusion Staged surgical treatment including radical debridement followed by delayed total joint replacement with custom-made endoprosthesis provided satisfactory functionality for the limb without signs of infectious and inflammatory activity at a follow-up period of more than a year.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.